Sheet 1 of 2



ATTY. DOCKET NO. PPUCATION NO. 9516-018-999 09/734,460

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Jerome B. Zeldis
FILING DATE GROUP

					December 11, 2000		To be assign	ned
	U.S. PATENT DOCUMENTS							
*EXAMIN INITIA	YER L		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CL	E	AA	3,536,809	10/27/70	Applezweig			
1		AB	3,598,123	8/10/71	Zaffaroni			
		AC	3,845,770	11/05/74	Theeuwes et al.			
	igsqcup	AD	3,916,899	11/04/75	Theeuwes et al.			
		AE	4,008,719	2/22/77	Theeuwes, et al.			• *
	11	AF	5,059,595	10/22/91	LeGrazie			
	$\perp \downarrow$	AG	5,073,543	12/17/91	Marshall, et al.			
	$\perp \downarrow$	АН	5,120,548	6/09/92	McClelland, et al.		···-	
	Ш	AI	5,354,556	10/11/94	Sparks, et al.			
	Ш	AJ	5,591,767	1/07/97	Mohr, et al.	:		
•	Ш	AK	5,593,990	1/14/97	D'Amato			
	Ш	AL	5,605,914	2/25/97	Muller	•		
		АМ	5,629,327	5/13/97	D'Amato			
		AN	5,635,517	6/03/97	Mulier et al.			
		AO	5,637,113	6/10/97	Tartaglia, et al.			
		AP	5,639,476	6/17/97	Oshlack, et al.			
		AQ	5,658,940	8/19/97	Muller et al.			-
		AR	5,674,533	10/07/97	Santus et al.			
		AS	5,698,579	12/16/97	Muller			
		AT	5,703,098	12/30/97	Muller et al.			
		AU	5,728,844	3/17/98	Muller et al.			
		AV	5,728,845	3/17/98	Muller et al.			
		AW	5,733,566	3/31/98	Lewis			
		AX	5,736,570	4/07/98	Muller et al.			
	$\perp$	AY	5,798,368	8/25/98	Muller et al.			
		AZ	5,801,195	9/01/98	Muller et al.			
		ВА	5,837,313	11/17/98	Ding et al.			
-01		вв	5,874,448	2/23/99	Muller et al.			
W	V	вс	5,877,200	3/02/99	Muller			

FOREIGN PATENT DOCUMENTS											
			DOCUMENT NUMBER	. TE	COUNTRY		CLASS	SUBCLASS	TRANS	LATION	
- 01	6			·	<del></del>				YES	NO.	
<u>u</u>	7	BE	WO 99/06041	2/11/99	PCT						
			OTHER REI	FERENCES (Incl	uding Author, Title, Date, Pertine	nt Pages, Etc.)				·	
Arnols, et al., 1998, "Intracoronary radiation for prevention of re- by stents", Circulation 98(19):2024-9.					for prevention of restenosis: dose	perturbations car	used			···	
JAN 3	6 2		Bachelerie et al., 1991, "HIV enhancer activity perpetuated by NF-kappa B induction on infection of monocytes", Nature 350(6320):709-12								
<u>څ</u> ړ , ,	PMP		Blaschke et al., 1979, "Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers", Arzneimittelforschung 29(10):1640-2.								
		ВІ	Brem, et al., 1991, "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas", J Neurosurg. 74(3):441-6.								
$\Box$		ВЈ	Casini, et al., 1964, Farma	ico Ed. Sci. 19:5	663						
<u> </u>		ВК	D'Amato et al., 1994, "Tha	lidomide is an i	hibitor of angiogenesis. Proc Natl	Acad Sci U S A 9	1(9):4082	2-5.			
		BL	Dbaibo et al., 1993, "Tumor necrosis factor-alpha (TNF-alpha) signal transduction through ceramide. Dissociation of growth inhibitory effects of TNF-alpha from activation of nuclear factor-kappa B*, J Biol Chem. 268(24):17762-6.								
		ВМ	Duh et al., 1989, "Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat", Proc Natl Acad Sci U S A. 86(15):5974-8.								
		BN	Eltchaninoff, et al., 1998, "Balloon angioplasty for the treatment of coronary in-stent restenosis: immediate results and 6-month angiographic recurrent restenosis rate. J Am Coll Cardiol.32(4):980-4.								
		во	Libby et al., 1992, "A cascade model for restenosis. A special case of atherosclerosis progression",  Circulation. 86(6 Suppl):III47-52.								
		ВР	Moreno et al., 1996, "Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina", Circulation 94(12):3098-102.								
		BQ	Muller, et al. "Thalidomide: From tragedy to new drug discovery", 1997, Chemtech 27(1):21-25								
ļ		BR	Shealy et al., 1965, "D- and L-thalidomide", Chem Ind. 24:1030-1.								
		BS	Suzuki and Packer. 1993, "Inhibition of NF-kappa B activation by vitamin E derivatives", Biochem Biophys Res Commun. 193(1):277-83								
;		вт	Takano, et al., 1998, ":High levels of circulating Macrophage Colony Stimulationg Factor (M-CSF) Predict Restenosis After Primary Angioplasty in Patients With Acute Myocardial Infraction", Circulation 98(17, supp):4437.								
U	٤	_B∪	Tardif et al., 1991, " Probucol and multivitamins in the prevention of restenosis after coronary angioplasty", N Engl J Med. 337(6):365-72.								
EXAMINER CHARLES EVANS DATE CONSIDERED 3.5.2002											

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAY 1 7 2001

		TECH CENTER 1600/2900									
					ATTY, DOCKET NO.				APPLICATION NO.		
					9516-018-999		09/734,460				
	LIST C	OF REFERENCES CITE	D BY APPLIC	CANT	APPLICANT						
		(Use several sheets if n	iecessary)	Jerome B. Zeldis							
			•	,	FILING DATE		GROUP				
					December 11, 2000	2000 1614 (6)					
U.S. PATENT DOCUMENTS											
'EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE			
as	8V	5,849,736	12/15/98	Wityak et al.							
	FOREIGN PATENT DOCUMENTS										
	· .	DOCUMENT NUMBER	DATE		COUNTRY CLAS			TRANS	SLATION		
						<b>l</b>		YES	NO -		
ae	вw	WO 00/10552	3/2/2000	PCT							
	вх	WO 99/58096	11/18/99	PCT							
	ВҮ	WO 98/08840	3/5/98	PCT		_					
	BZ	WO 96/11209	4/18/96	PCT							
Cle	CA	0 688 771	12/27/95	EPO (In Germa	an)				х		
		OTHER RE	FERENCES (In	ncluding Author, Title	e, Date, Pertinent Pages, Etc.)						
			į.								
							-				
EXAMINER		jarosse L. E	vans	DATE (	considered 35.0	52					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											